<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01963403</url>
  </required_header>
  <id_info>
    <org_study_id>478388</org_study_id>
    <secondary_id>MISP 50618</secondary_id>
    <nct_id>NCT01963403</nct_id>
  </id_info>
  <brief_title>Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With an Oral Contraceptive</brief_title>
  <acronym>ROBI</acronym>
  <official_title>Relief of Bleeding on the Implant: Treatment of Unacceptable Bleeding Patterns in ETG Implant Users With a Combined Oral Contraceptive: A Placebo-Controlled Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This double-blinded, placebo-controlled, randomized trial will compare the effects of the use
      of a combined oral contraceptive pill to a placebo pill for women who are experiencing
      irregular and/or heavy bleeding associated with the use of an etonogestrel (ETG) implant.

      The hypothesis of the study is:

        -  Use of combined oral contraceptive will significantly improve bleeding patterns for
           users of ETG implant

        -  Continuation rate of ETG implant users will be increased by use of combined oral
           contraceptive in women desiring ETG implant removal because of the undesirable bleeding

        -  Adverse events will be uncommon and acceptable to women who use a combined oral
           contraceptive with the ETG implant
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women who are experiencing irregular and/or heavy bleeding associated with the use of an
      etonogestrel (ETG) implant will be recruited for this study. Women who have bothersome
      bleeding will be randomized to use either a combined oral contraceptive pill or a placebo
      pill.

      Participants will take one pill every day and record their bleeding patterns on a daily
      diary.

      Participants will have one screening/enrollment visit, two in-person follow up visits, and
      one telephone follow up contact. Subjects will be enrolled for a total of 84 days (three
      months).

      Participants will be assigned to a treatment group at her screening/enrollment visit. Her
      first follow up visit will occur 22-28 days after her enrollment. Participants can choose to:

        -  Continue use of assigned treatment medication

        -  Discontinue use of assigned treatment medication, but use an open-label combined oral
           contraceptive pill

        -  Discontinue the use of assigned treatment medication, decline use of an open-label
           combined oral contraceptive pill

        -  Discontinue use of ETG implant.

      Participants who choose to continue use of ETG implant will have a follow up telephone
      contact 50-56 days after her enrollment visit. A final in-person visit will occur 78-84 days
      after enrollment. Bleeding patterns will be assessed by daily bleeding diaries completed by
      the participant.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Futility of recruitment
  </why_stopped>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">July 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Bleeding Improvement</measure>
    <time_frame>Bleeding improvement will be evaluated during first cycle of study treatment (28 days)</time_frame>
    <description>Bleeding improvement will be measured by participant response to the question of whether she feels her bleeding is improved and she is satisfied with the treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Adverse events will be evaluated at each contact (visits at 1 and 3 months, phone contact at 2 months) with the participant</time_frame>
    <description>Participants will be evaluated for adverse events while using a combined oral contraceptive with ETG implant.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants withTreatment Success or Failure</measure>
    <time_frame>Evaluated at follow up visits at 1 month and, if subject continues after 1st month, again at 3 months</time_frame>
    <description>Treatment success will be measured by desire to continue treatment because the initial treatment made the bleeding better.
Partial failure of the study treatment will be measured by the desire to continue treatment because the initial treatment did not work
Complete failure of treatment will be measured by the desire to:
discontinue treatment because it did not work; no further treatment requested
ETG implant removal
Desire to use non-study treatment</description>
  </other_outcome>
  <other_outcome>
    <measure>Bleeding Patterns and Number of Participants With Bleeding Improvement</measure>
    <time_frame>Evaluated at follow up visits at 1 month and, if subject continues after 1st month, again at 3 months</time_frame>
    <description>Bleeding improvement in women who received placebo but opted for open-label treatment after first cycle
Bleeding improvement over the 84 days of study participation
Bleeding patterns in placebo vs. combined oral contraceptive users</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Abnormal Uterine Bleeding, Unspecified</condition>
  <condition>Uterine Bleeding Heavy</condition>
  <arm_group>
    <arm_group_label>EE 30mcg/LNG 150mcg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EE 30mcg/LNG 150mcg</intervention_name>
    <description>1 pill per day; daily during study participation (up to 84 days)</description>
    <arm_group_label>EE 30mcg/LNG 150mcg</arm_group_label>
    <other_name>Levlen28</other_name>
    <other_name>Levora</other_name>
    <other_name>Portia 28</other_name>
    <other_name>Altavera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 pill per day; daily during study participation (up to 84 days)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women who have an ETG implant in place

          -  Women who subjectively experience the side effect of an undesirable bleeding profile
             such as bleeding irregularity or heavy flow after ETG implant was placed and who
             desire intervention for this side effect by either treatment of bleeding or removal of
             the implant

          -  Age 14 years an older, inclusive

        Exclusion Criteria:

          -  Irregular or heavy bleeding from an etiology other than ETG use (e.g. fibroids,
             cervical polyp, or other organic cause of bleeding)

          -  Has attempted prescription treatment for menstrual side effects while using ETG
             implant

          -  Has one or more of the conditions considered Category 3 (risks outweigh benefits) or
             Category 4 (unacceptable health risk) for estrogen-containing oral contraceptives by
             the Center for Disease Control Medical Eligibility Criteria for Contraceptive Use:

               -  Current or history of heart or vascular diseases, including deep venous
                  thrombosis, pulmonary embolism, known thrombogenic mutations, peripartum
                  cardiomyopathy, and complicated valvular heart disease

               -  Hypertension, even if adequately controlled

               -  Diabetes with vascular involvement

               -  Headaches with focal aura, or migraines in women age 35 and older even without
                  focal aura

               -  Major surgery with prolonged immobilization

               -  Breast cancer (current or past)

               -  Severe (decompensated) cirrhosis

               -  Acute or flare viral hepatitis

               -  Breastfeeding less than 1 month postpartum

               -  Post-partum less than 3 weeks

               -  35 years of age and older and smoking

               -  Multiple risk factors for arterial cardiovascular disease

               -  Systemic Lupus Erythematosus with positive or unknown antiphospholipid antibodies

               -  Current symptomatic gallbladder disease or history of cholestasis related to past
                  combined oral contraceptive use

               -  On certain anticonvulsants (phenytoin, carbamazepine, barbiturates, primidone,
                  topiramate, oxcarbazepine, lamotrigine)

               -  On Ritonavir-boosted protease inhibitors for antiretroviral therapy

          -  Issues or concerns, in the judgment of the investigator, that may compromise the
             safety of the subject, impact the subject's adherence to the protocol requirements, or
             confound the reliability of the data acquired in this study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mitchell Creinin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Melody Hou, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Davis Department of Obstetrics and Gynecology</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Department of Obstetrics and Gynecology</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hou MY, McNicholas C, Creinin MD. Combined oral contraceptive treatment for bleeding complaints with the etonogestrel contraceptive implant: a randomised controlled trial. Eur J Contracept Reprod Health Care. 2016 Oct;21(5):361-6. doi: 10.1080/13625187.2016.1210122. Epub 2016 Jul 15.</citation>
    <PMID>27419258</PMID>
  </results_reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 10, 2013</study_first_submitted>
  <study_first_submitted_qc>October 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2013</study_first_posted>
  <results_first_submitted>December 19, 2016</results_first_submitted>
  <results_first_submitted_qc>April 4, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2017</results_first_posted>
  <last_update_submitted>April 4, 2017</last_update_submitted>
  <last_update_submitted_qc>April 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Davis</investigator_affiliation>
    <investigator_full_name>Mitchell Creinin, MD</investigator_full_name>
    <investigator_title>Professor and Director of Family Planning</investigator_title>
  </responsible_party>
  <keyword>etonogestrel implant</keyword>
  <keyword>birth control</keyword>
  <keyword>irregular bleeding</keyword>
  <keyword>heavy bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Uterine Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>EE 30mcg/LNG 150mcg</title>
          <description>combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
EE 30mcg/LNG 150mcg: 1 pill per day; daily during study participation (up to 84 days)</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo
Placebo: 1 pill per day; daily during study participation (up to 84 days)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11">Follow-up over three months</participants>
                <participants group_id="P2" count="9">Follow-up over three months</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Implant removal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>EE 30mcg/LNG 150mcg</title>
          <description>combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
EE 30mcg/LNG 150mcg: 1 pill per day; daily during study participation (up to 84 days)</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo
Placebo: 1 pill per day; daily during study participation (up to 84 days)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.4" spread="3.8"/>
                    <measurement group_id="B2" value="25.8" spread="5.0"/>
                    <measurement group_id="B3" value="25.6" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Primary reason for implant</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Contraception</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bleeding Problem</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Dysmenorrhea</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of implant use</title>
          <units>days</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343" lower_limit="25" upper_limit="764"/>
                    <measurement group_id="B2" value="109" lower_limit="41" upper_limit="518"/>
                    <measurement group_id="B3" value="144.5" lower_limit="25" upper_limit="764"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>intervention requested before enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>implant removal</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hormonal treatment</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>'Some treatment'</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Bleeding Improvement</title>
        <description>Bleeding improvement will be measured by participant response to the question of whether she feels her bleeding is improved and she is satisfied with the treatment.</description>
        <time_frame>Bleeding improvement will be evaluated during first cycle of study treatment (28 days)</time_frame>
        <population>1 person in each group LTFU at one month, which was the primary outcome</population>
        <group_list>
          <group group_id="O1">
            <title>EE 30mcg/LNG 150mcg</title>
            <description>combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
EE 30mcg/LNG 150mcg: 1 pill per day; daily during study participation (up to 84 days)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 pill per day; daily during study participation (up to 84 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bleeding Improvement</title>
          <description>Bleeding improvement will be measured by participant response to the question of whether she feels her bleeding is improved and she is satisfied with the treatment.</description>
          <population>1 person in each group LTFU at one month, which was the primary outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Significant improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Slight improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Slightly worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Significantly worse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>Participants will be evaluated for adverse events while using a combined oral contraceptive with ETG implant.</description>
        <time_frame>Adverse events will be evaluated at each contact (visits at 1 and 3 months, phone contact at 2 months) with the participant</time_frame>
        <population>Outcomes at one month; 1 person LTFU at one month in each group</population>
        <group_list>
          <group group_id="O1">
            <title>EE 30mcg/LNG 150mcg</title>
            <description>combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
EE 30mcg/LNG 150mcg: 1 pill per day; daily during study participation (up to 84 days)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 pill per day; daily during study participation (up to 84 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>Participants will be evaluated for adverse events while using a combined oral contraceptive with ETG implant.</description>
          <population>Outcomes at one month; 1 person LTFU at one month in each group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Headache</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Nausea/vomiting</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cramping</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Mood change</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>None of above</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants withTreatment Success or Failure</title>
        <description>Treatment success will be measured by desire to continue treatment because the initial treatment made the bleeding better.
Partial failure of the study treatment will be measured by the desire to continue treatment because the initial treatment did not work
Complete failure of treatment will be measured by the desire to:
discontinue treatment because it did not work; no further treatment requested
ETG implant removal
Desire to use non-study treatment</description>
        <time_frame>Evaluated at follow up visits at 1 month and, if subject continues after 1st month, again at 3 months</time_frame>
        <population>one month evaluation; 1 subject LTFU at one month in each group</population>
        <group_list>
          <group group_id="O1">
            <title>EE 30mcg/LNG 150mcg</title>
            <description>combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
EE 30mcg/LNG 150mcg: 1 pill per day; daily during study participation (up to 84 days)</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo
Placebo: 1 pill per day; daily during study participation (up to 84 days)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants withTreatment Success or Failure</title>
          <description>Treatment success will be measured by desire to continue treatment because the initial treatment made the bleeding better.
Partial failure of the study treatment will be measured by the desire to continue treatment because the initial treatment did not work
Complete failure of treatment will be measured by the desire to:
discontinue treatment because it did not work; no further treatment requested
ETG implant removal
Desire to use non-study treatment</description>
          <population>one month evaluation; 1 subject LTFU at one month in each group</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Continued assigned treatment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Desired COC prescription</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Desired no treatment</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Implant removal</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Bleeding Patterns and Number of Participants With Bleeding Improvement</title>
        <description>Bleeding improvement in women who received placebo but opted for open-label treatment after first cycle
Bleeding improvement over the 84 days of study participation
Bleeding patterns in placebo vs. combined oral contraceptive users</description>
        <time_frame>Evaluated at follow up visits at 1 month and, if subject continues after 1st month, again at 3 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Used COC at Any Time During 3 Months</title>
          </group>
          <group group_id="O2">
            <title>No Use of COC at Any Time During 3 Months</title>
          </group>
        </group_list>
        <measure>
          <title>Bleeding Patterns and Number of Participants With Bleeding Improvement</title>
          <description>Bleeding improvement in women who received placebo but opted for open-label treatment after first cycle
Bleeding improvement over the 84 days of study participation
Bleeding patterns in placebo vs. combined oral contraceptive users</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bleeding improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No bleeding improvement</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 84 days on either medication or placebo.</time_frame>
      <desc>Adverse events for the drug arms reported combined arms. Placebo adverse events are reported for the single arm.</desc>
      <group_list>
        <group group_id="E1">
          <title>EE 30mcg/LNG 150mcg</title>
          <description>Combined oral contraceptive pill: ethinyl estradiol (EE) 30mcg/levonorgestrel 150mcg); 1 pill per day; daily during study participation (up to 84 days)
EE 30mcg/LNG 150mcg: 1 pill per day; daily during study participation (up to 84 days)</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo: 1 pill per day; daily during study participation (up to 84 days)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Cramping</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Mood change</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Mitchell Creinin</name_or_title>
      <organization>UC Davis</organization>
      <phone>916-734-6670</phone>
      <email>mdcreinin@ucdavis.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

